Background
Constitutional
MLH1
epimutations are characterised by monoallelic methylation of the
MLH1
promoter throughout normal tissues, accompanied by allele-specific silencing. The mechanism underlying primary
MLH1
epimutations is currently unknown. The aim of this study was to perform an in-depth characterisation of constitutional
MLH1
epimutations targeting the aberrantly methylated region around
MLH1
and other genomic loci.
Methods
Twelve
MLH1
epimutation carriers, 61 Lynch syndrome patients, and 41 healthy controls, were analysed by Infinium 450 K array. Targeted molecular techniques were used to characterise the
MLH1
epimutation carriers and their inheritance pattern.
Results
No nucleotide or structural variants were identified
in-cis
on the epimutated allele in 10 carriers, in which inter-generational methylation erasure was demonstrated in two, suggesting primary type of epimutation. CNVs outside the
MLH1
locus were found in two cases.
EPM2AIP1-MLH1
CpG island was identified as the sole differentially methylated region in
MLH1
epimutation carriers compared to controls.
Conclusion
Primary constitutional
MLH1
epimutations arise as a focal epigenetic event at the
EPM2AIP1-MLH1
CpG island in the absence of
cis
-acting genetic variants. Further molecular characterisation is needed to elucidate the mechanistic basis of
MLH1
epimutations and their heritability/reversibility.
Fabry disease (FD) is a rare, X-linked disorder caused by mutations in the GLA gene encoding the enzyme α-galactosidase A. Complete or partial deficiency in this enzyme leads to intracellular accumulation of globotriaosylceramide (Gb3) and other glycosphingolipids
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.